Get started
Live feed
·
INSIDERFilingvia Quantisnow
Bristol-Myers Squibb Company logo

Bristol-Myers Squibb (BMY) executive Meyers acquired 6,281 shares

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow AI summary

EVP Meyers vested 6,281 RSUs, with 2,665 shares withheld for taxes at $62.48; direct holdings now 33,977 shares.

Insider transactions reported

Gregory Scott Meyers (EVP, Chief Digital & Tech Off. at Bristol-Myers Squibb Company, BMY) reported that they acquired 6,281 shares, and gave up 2,665 shares at $62.48 to cover taxes or an exercise price on Nov 1, 2026. After these transactions the filing shows 33,977 shares held directly.

Reporting person
Meyers Gregory Scott
Role
EVP, Chief Digital & Tech Off.
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Nov 1, 2026Exercise or conversion of a derivative (M)Common Stock, $0.10 par value1+6,281--36,642 direct
Nov 1, 2026Shares withheld for taxes or exercise price (F)Common Stock, $0.10 par value2-2,665$62.48$167K33,977 direct

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Nov 1, 2026Exercise or conversion of a derivative (M)Restricted Stock UnitsOn 6,281 Common Stock, $0.10 par value3, 4-6,281--6,281 direct

Holdings before and after

  • Common Stock, $0.10 par value: 30,361 to 33,977 direct
  • Restricted Stock Units: 12,562 to 6,281 direct

Footnotes from the filing

  1. 1. Represents vesting of one-third of restricted stock units granted on November 1, 2024.
  2. 2. Shares withheld for payment of taxes upon vesting of awards.
  3. 3. Each restricted stock unit converts into one share of common stock upon vesting.
  4. 4. The restricted stock units vest in three equal annual installments beginning on November 1, 2025.

Transaction codes in this filing

Exercise or conversion of a derivative:
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Shares withheld for taxes or exercise price:
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.

FAQ

What did Meyers report in this BMY Form 4?

Gregory Scott Meyers (EVP, Chief Digital & Tech Off. at Bristol-Myers Squibb Company, BMY) reported that they acquired 6,281 shares, and gave up 2,665 shares at $62.48 to cover taxes or an exercise price on Nov 1, 2026. After these transactions the filing shows 33,977 shares held directly.

How many BMY shares does Meyers hold after this filing?

The filing shows 33,977 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

What does transaction code M mean on an SEC Form 4?

Code M marks the exercise or conversion of an option or other derivative under an exempt plan.

Historical context for BMY

Across the 24 sessions after earlier BMY headlines, the stock closed higher 9 times and lower 15 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

BMY close-to-close change in the session after earlier headlines
SessionEarlier headlineBMYSPY
Oct 29, 2026Bristol Myers Squibb Reports Third Quarter Financial Results for 2026+1.4%-0.4%
Oct 26, 2026Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study+0.2%+0.7%
Oct 23, 2026Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026and 2 other headlines that session-2.4%-0.5%
Oct 19, 2026Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026-1.5%+0.4%
Oct 12, 2026Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETsand 1 other headline that session-2.6%-0.1%
Oct 8, 2026Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...-0.2%-0.4%

Earlier insider filings at BMY

Quantisnow market dataNYSE
Bristol-Myers Squibb Company logo
BMY
Bristol-Myers Squibb Company
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for BMY

Follow BMY and get a push notification the moment its next story breaks.

Full BMY profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMY (Bristol-Myers Squibb Company) and more on Quantisnow.